| Line Item | 2026-01-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.1M | -9.4% | +6.5% |
| SG&A Expense | $1.5M | -9.9% | -0.5% |
| Operating Income | -$7.5M | +9.5% | -5.0% |
| Net Income | -$7.2M | +11.9% | -14.8% |
| EPS (Basic) | -$2.58 | +40.7% | -10.7% |
| EPS (Diluted) | -$2.58 | +40.7% | -10.7% |
| Line Item | 2026-01-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $29.9M | +1001.8% | +496.4% |
| Short-term Investments | $7.4M | -1.2% | — |
| Current Assets | $32.2M | +183.6% | +349.3% |
| Total Assets | $33.6M | +156.9% | +258.8% |
| Current Liabilities | $3.2M | -4.0% | -39.1% |
| Stockholders' Equity | $30.2M |
| Line Item | 2026-01-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$15.7M | -103.4% | — |
| Investing Cash Flow | $7.2M | +9710.0% | — |
| Financing Cash Flow | $27.9M | — | — |
| +836.3% |